Brokerages Set ProQR Therapeutics N.V. (NASDAQ:PRQR) Target Price at $6.80

ProQR Therapeutics N.V. (NASDAQ:PRQR) has been given a consensus rating of “Moderate Buy” by the eight brokerages that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $6.80.

Several equities analysts have issued reports on PRQR shares. Wall Street Zen upgraded shares of ProQR Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Saturday, March 14th. Oppenheimer assumed coverage on shares of ProQR Therapeutics in a report on Thursday, March 12th. They set an “outperform” rating and a $9.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of ProQR Therapeutics in a research note on Thursday, January 22nd. Finally, Citigroup restated a “market outperform” rating on shares of ProQR Therapeutics in a report on Friday, March 13th.

Institutional Investors Weigh In On ProQR Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in PRQR. Osaic Holdings Inc. lifted its stake in shares of ProQR Therapeutics by 59.6% in the second quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 4,500 shares during the period. Persistent Asset Partners Ltd increased its position in ProQR Therapeutics by 24.5% during the 4th quarter. Persistent Asset Partners Ltd now owns 45,154 shares of the biopharmaceutical company’s stock valued at $91,000 after purchasing an additional 8,874 shares during the period. Diadema Partners LP increased its position in ProQR Therapeutics by 6.2% during the 4th quarter. Diadema Partners LP now owns 167,532 shares of the biopharmaceutical company’s stock valued at $338,000 after purchasing an additional 9,838 shares during the period. Raymond James Financial Inc. raised its holdings in ProQR Therapeutics by 15.2% during the 3rd quarter. Raymond James Financial Inc. now owns 110,270 shares of the biopharmaceutical company’s stock worth $235,000 after purchasing an additional 14,549 shares during the last quarter. Finally, OneDigital Investment Advisors LLC raised its holdings in ProQR Therapeutics by 23.1% during the 3rd quarter. OneDigital Investment Advisors LLC now owns 80,000 shares of the biopharmaceutical company’s stock worth $170,000 after purchasing an additional 15,000 shares during the last quarter. Institutional investors and hedge funds own 32.65% of the company’s stock.

ProQR Therapeutics Stock Performance

NASDAQ:PRQR opened at $1.71 on Wednesday. The stock has a market cap of $180.17 million, a P/E ratio of -3.72 and a beta of 0.10. The stock’s 50-day moving average is $1.59 and its 200-day moving average is $2.00. ProQR Therapeutics has a 1-year low of $1.07 and a 1-year high of $3.10.

ProQR Therapeutics (NASDAQ:PRQR) last issued its quarterly earnings data on Thursday, March 12th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.01). ProQR Therapeutics had a negative net margin of 255.83% and a negative return on equity of 65.89%. The business had revenue of $5.53 million during the quarter, compared to the consensus estimate of $6.12 million. As a group, equities analysts forecast that ProQR Therapeutics will post -0.31 EPS for the current year.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.